Pharm Exec

FDA Approves Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...
News Medical

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Moreover, those patients treated with SIR-Spheres Y-90 resin microspheres who reported treatment-related side effects experienced a median of only 5 such events over the course of the SARAH study, ...
Finanznachrichten

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres Y-90 resin microspheres

Physicians and employees recognized for their role in this milestone and impact made on patient lives WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of ...
Finanznachrichten

Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...